Previous 10 | Next 10 |
AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD) AC Immune to receive a milestone payment from LMI for progress into late-stage product development LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -...
AC Immune ( NASDAQ: ACIU ) said it received a new grant of $0.5M from the Michael J. Fox Foundation for Parkinson's Research (MJFF) to continue development of its diagnostic imaging agent ACI-12589 for Parkinson's Disease. The company added that it has received...
Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brain New grant funding will pave the way for enhanced clinical studies Total funding from The Michael J. Fox Foundation for AC Im...
Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalities Integrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synuclein Precisely target...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for a breakdown of the biggest pre-market stock movers for Tuesday and the news that has them moving. Moving stocks this morning is an acquisition, a senior note of...
Webinar to take place on Wednesday, August 24 th at 10:00 AM ET / 4:00 PM CET Discussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ...
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistical...
AC Immune press release ( NASDAQ: ACIU ): Q2 Non-GAAP EPS of -CHF0.23 in-line. The Company had a total cash balance of CHF 154.1 million, composed of CHF 63.1 million in cash and cash equivalents and CHF 91.0 million in short-term financial assets. The Company reported...
Three clinical readouts delivered year to date; four more expected by year-end First patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome Crenezumab API ADAD stud...
New data from the API ADAD Study to be presented in AAIC Focused Topic Session New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease First-time presentation of innovative biomarker-based translational clinical...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...